United Therapeutics - UTHR Stock Forecast, Price & News

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $217.10 on Friday. The company has a market capitalization of $9.88 billion, a price-to-earnings ratio of 16.43, a PEG ratio of 4.53 and a beta of 0.53. United Therapeutics has a twelve month low of $158.38 and a twelve month high of $245.48. The stock has a fifty day simple moving average of $229.49 and a 200 day simple moving average of $203.78. The company has a quick ratio of 7.83, a current ratio of 8.10 and a debt-to-equity ratio of 0.19.

United Therapeutics (NASDAQ:UTHR - Get Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported $2.41 earnings per share for the quarter, missing analysts' consensus estimates of $4.10 by ($1.69). United Therapeutics had a return on equity of 15.50% and a net margin of 35.27%. The business had revenue of $466.90 million for the quarter, compared to analyst estimates of $461.06 million. During the same quarter in the previous year, the business posted $3.65 earnings per share. The business's revenue was up 4.6% on a year-over-year basis. Sell-side analysts expect that United Therapeutics will post 15.21 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on UTHR shares. Oppenheimer upped their target price on United Therapeutics from $275.00 to $300.00 in a research note on Thursday, May 5th. Jefferies Financial Group upped their target price on United Therapeutics from $223.00 to $245.00 in a research note on Tuesday, May 24th. Wedbush upped their target price on United Therapeutics from $236.00 to $263.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 24th. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, August 4th. Finally, Credit Suisse Group increased their price target on United Therapeutics from $219.00 to $247.00 and gave the company an "outperform" rating in a research note on Tuesday, May 24th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $250.14.

Insiders Place Their Bets

In other United Therapeutics news, Director Christopher Causey sold 5,000 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $223.54, for a total transaction of $1,117,700.00. Following the completion of the sale, the director now directly owns 750 shares in the company, valued at approximately $167,655. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other United Therapeutics news, Director Christopher Causey sold 5,000 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $223.54, for a total transaction of $1,117,700.00. Following the completion of the sale, the director now directly owns 750 shares in the company, valued at approximately $167,655. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction dated Thursday, May 19th. The stock was sold at an average price of $183.43, for a total value of $1,100,580.00. Following the sale, the executive vice president now owns 36,397 shares of the company's stock, valued at $6,676,301.71. The disclosure for this sale can be found here. In the last ninety days, insiders sold 52,712 shares of company stock worth $11,740,574. Company insiders own 12.40% of the company's stock.